PolyPeptide Shareholders Approve Board Overhaul and Removal of Transfer Restrictions Ahead of Samsung Biologics Takeover

PolyPeptide Group AG shareholders approved all board proposals at an extraordinary general meeting, electing a new board and agreeing to remove transfer restrictions and voting limitations, moves that are conditional on the settlement of a public tender offer by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd. The decisions, announced via NEWMEDIAWIRE, effectively dismantle the company’s existing takeover defenses and install leadership aligned with the incoming acquirer, marking a pivotal step in the Swiss CDMO’s shift into South Korean ownership.

The shareholder vote elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang and Joonkyung Seong as board members, with Rim as chair and Cheol Woo Ryu and Seungho Ryu joining the Remuneration and Nomination Committee. All elections take effect only upon settlement of Samsung Peptide AG’s offer for all publicly held registered shares. Shareholders also resolved to remove the transfer restrictions (Vinkulierung) and voting limitations (Stimmrechtsbeschränkungen) from PolyPeptide’s articles of association, subject to the satisfaction or waiver of all offer conditions in the 31 August 2026 offer prospectus, except for the condition in section B.7.1(e).

The removal of transfer restrictions is particularly significant because such clauses often shield Swiss companies from unwanted suitors by limiting share registration and voting rights. Their elimination, once effective, would simplify the transfer of shares to Samsung Peptide AG and reduce structural barriers to completing the takeover. The board reshuffle similarly matters: by installing Samsung-affiliated directors before settlement, PolyPeptide is preparing for a controlled handover of governance and strategy at a company that specializes in peptide-based active pharmaceutical ingredients, a fast-growing segment driven by metabolic disease therapies including GLP-1 drugs.

PolyPeptide operates six GMP-certified facilities across Europe, the U.S. and India and serves pharma and biotech customers from pre-pre-clinical to commercial stages. A change of control at such a CDMO could affect supply relationships and capacity planning for customers developing peptide therapeutics. The board’s decision to condition the governance changes on the offer prospectus suggests the parties aim to avoid any gap between shareholder approval and deal closing. Additional details are available in the PolyPeptide_EGM Results 2026_ENG document, and the company’s profile is outlined at polypeptide.com.

For investors, the outcome reduces uncertainty around the offer’s governance conditions, though the elections and articles amendment remain contingent on settlement and the waiver or satisfaction of offer conditions. The vote also signals that PolyPeptide’s board and shareholders are aligned on the transaction, lowering the risk of a contested process. As a result, the market’s focus shifts to the remaining regulatory and closing steps that will determine when Samsung Biologics formally assumes control of the peptide specialist.